Former Pfizer Execs Shop L/S Equity Hedge Fund

Jul 16 2007 | 6:11am ET

Groton, Conn.-based Do Asset Management has begun marketing its $10 million equity long/short fund to outside investors, with the goal of reaching $250 million by year-end.   

The fund, which launched in October 2004, is derived from the firm’s foundation as a provider of valuation and risk management to the pharmaceutical, biotech, and energy sectors. “The fund was started to apply our know-how of private asset valuation in the public markets,” said co-founder Gill Eapen. “We have a long/short strategy that tends to be market neutral and we don’t take any sector or size exposure. We don’t generally buy beta risk [instead] going after alpha.”

Eapen added that the fund can be customized for either institutional investors looking for low beta returns or high-net worth investors seeking absolute returns. The fund is being shopped by third-party marketer Alpha Introductions. 

The long/short offering, DoAM’s flagship, returned 22% on an annualized basis and 9.4% YTD. Its 1:1 levered version has fared even better, with a 25.4% annualized return and 14.6% YTD. The fund charges 2% for management and 20% for performance, with a $500,000 for investments in the fund and $3 million to $5 million for separately-managed accounts.

Eapen is a former group director of Pfizer, responsible for the company’s portfolio management. Former Pfizer executives Pierre Etienne, Dilip Mehta, Craig Saxton and Ian Williams round out DoAM’s management team.


In Depth

GSAM’s Papagiannis on Liquid Alternatives

May 25 2016 | 5:07pm ET

The popularity of liquid alternatives strategies has blossomed in recent years,...

Lifestyle

From Modern Trader: Stephen Curry is a Black Swan

May 18 2016 | 7:43pm ET

What do the rise of the Internet, the sinking of the Titanic, 9/11, and Stephen...

Guest Contributor

LendingClub and the Question of Internal Hedge Funds

May 19 2016 | 8:42pm ET

Peer-to-peer lending platform LendingClub Corp. has been in the news since the firm...